【摘要】 目的评价重组人B型利钠肽(rhBNP)对扩张型心肌病心力衰竭治疗的近期临床疗效。方法入选扩张型心肌病心力衰竭患者121例,心功能Ⅲ~Ⅳ级,分为常规治疗组(对照组,n=61)和rhBNP治疗组(rhBNP组,n=60),记录病史,并观察两组治疗前、后临床症状、心脏彩超、心功能状态、血浆N末端B型钠尿肽原(NT-proBNP)水平和肾功能变化。结果治疗72h后,rhBNP组NT-proBNP水平显著低于对照组(P<0.01);治疗1周时,rhBNP组LVEDd显著小于对照组(P=0.033),两组LVEF均升高,rhBNP组升高更显著(P<0.01);治疗1周后rhBNP组的总有效率(91.6%)与对照组(72.1%)比较,差异有统计学意义(P=0.005);rhBNP组平均住院时间也明显短于对照组(P=0.041);两组患者出现主要不良心血管事件(MACE)的比例比较,差异无统计学意义(P=0.492)。结论 rhBNP治疗扩张型心肌病急性失代偿期患者是安全有效的。更多还原

【Abstract】 Objective To evaluate the short term clinical efficacy of recombinant human B-type natriuretic peptide(rhBNP)in the treatment of dilated cardiomyopathy complicating heart failure.Methods 121 patients with dilated cardiomyopathy complicating heart failure were selected,the cardiac function gradeⅢ-Ⅳ,and randomly divided into the conventional treatment group(control group,n=61)and the rhBNP treatment group(rhBNP group,n=60).The disease history was recorded and clinical symptoms,heart color echocardiography,cardiac function,renal function and plasma NT-proBNP levels were observed before and after treatment.Results The NT-proBNP level after 72 htreament in the rhBNP group was significantly lower than that in the control group(P<0.01);LVEDd after 1 week treatment in the rhBNP group was significantly lower than that in the control group(P=0.033);LVEF was increased in the both groups,but the increase in the rhBNP group was more significant compared with the control group(P<0.01).The total effective rate was 91.6%in the rhBNP group and 72.1%in the control group with statistical differnece between the two groups(P=0.005);the average hospital stay time in the rhBNP group was significantly shorter than that in the control group(P=0.041).The proportion of the major adverse cardiovascular events(MACE)occurrence had no statistical difference between the two groups(P=0.492).Conclusion rhBNP is safe and effective in treating the acute decompensation of dilated cardiomyopathy.更多还原